While the observed decrease in active MEK levels in RocA-treated NRAS-mutant melanoma cells suggests that CRAF–PHB interactions may partly contribute to the control of ERK signaling, the concomitant loss of the negative feedback control leads to potent ERK hyperactivation also in this cellular context. This evidence concerns the gene MAP2K7 and melanoma.